769 related articles for article (PubMed ID: 36524120)
1. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel copper metabolism-related risk model to predict prognosis and tumor microenvironment of patients with stomach adenocarcinoma.
Sun D; Zhang H; Zhang C
Front Pharmacol; 2023; 14():1185418. PubMed ID: 37284310
[No Abstract] [Full Text] [Related]
3. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
4. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
5. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.
Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J
Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
7. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
8. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
9. Lipid metabolism-related gene prognostic index (LMRGPI) reveals distinct prognosis and treatment patterns for patients with early-stage pulmonary adenocarcinoma.
Jiang A; Chen X; Zheng H; Liu N; Ding Q; Li Y; Fan C; Fu X; Liang X; Tian T; Ruan Z; Yao Y
Int J Med Sci; 2022; 19(4):711-728. PubMed ID: 35582412
[No Abstract] [Full Text] [Related]
10. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
11. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
[TBL] [Abstract][Full Text] [Related]
12. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B
Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619
[TBL] [Abstract][Full Text] [Related]
13. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
14. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma.
Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C
Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818
[TBL] [Abstract][Full Text] [Related]
15. Identification of metabolism-related gene signature in lung adenocarcinoma.
Wang N; Wang H
Medicine (Baltimore); 2023 Nov; 102(47):e36267. PubMed ID: 38013279
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
Huang D; Tang E; Zhang T; Xu G
Front Immunol; 2022; 13():916284. PubMed ID: 35860256
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
18. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
Li F; Ge D; Sun SL
BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
[TBL] [Abstract][Full Text] [Related]
19. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
20. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]